Lortaan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lortaan

Property Description
Active ingredient Losartan potassium
Form Oral film-coated tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Management of high blood pressure (Hypertension)
Origin Synthetic compound

Lortaan is the brand name for a prescription-only medicine whose active substance is Losartan potassium. It is manufactured by Organon and is part of the key group of antihypertensive agents known as Angiotensin II Receptor Blockers (ARBs), a classification based on its pharmacological properties. Its general purpose is clinically recognized for providing effective management of elevated blood pressure.

The core compound, Losartan, is a synthetic compound, specifically a non-peptide Phenyltetrazole derivative. The Lortaan brand is a single-ingredient product, delivered for systemic administration as an oral film-coated tablet. This standardized dosage form is distinct from related combination products that pair Losartan with a diuretic.

Lortaan’s high-level mechanism involves a targeted hormone blockade within the body’s pressure-regulating renin-angiotensin system (RAS). It functions through selective antagonism, directly binding to the Angiotensin II Type 1 (AT1) receptor. This action prevents the powerful hormone Angiotensin II from causing vasoconstriction, promoting vasodilation (vessel widening) instead. This mechanism is recognized as the principal driver for lowering high blood pressure and easing strain on the cardiovascular system in adult patients.

Regulatory References

  1. National Library of Medicine, MedlinePlus

What side effects are possible with Lortaan?

Possible side effects and safety information

The officially documented safety profile for Lortaan (Losartan potassium) details possible side effects according to frequency and the physiological systems affected, as established in government-approved regulatory labeling.


Documented Adverse Reactions by Frequency

Based on clinical trial data, a core group of reactions is classified as common (occurring in 1% of patients). These include symptoms such as dizziness, headache, upper respiratory infection, back pain, and diarrhea. General reactions like asthenia (fatigue) and local swelling (edema) are also commonly reported.

Reactions documented as uncommon (occurring in 0.1% to 1%) include somnolence, vomiting, and skin reactions such as urticaria (hives) and rash.

Rare reactions (occurring in less than 0.1%) are critical safety concerns. These include angioedema (swelling of the face, lips, tongue, and/or throat) and cerebrovascular accident (stroke).


Serious Adverse Safety Constraints

Official labeling outlines several serious safety constraints. Drugs that act on the renin-angiotensin system, including Losartan, are associated with a high risk of Fetal Toxicity when used during the second and third trimesters of pregnancy, which can result in fetal injury and death. Discontinuation is required as soon as pregnancy is detected. Other serious systemic issues documented include the potential for acute renal failure, significant elevations in serum potassium levels (hyperkalemia), and liver function abnormalities (hepatitis).

Population-Specific Considerations

Safety constraints are defined for specific populations. Losartan is officially contraindicated in patients with severe hepatic impairment due to the expectation of significantly increased plasma concentrations. Additionally, symptomatic hypotension is noted as being more likely to occur upon the initiation of treatment in volume- or salt-depleted patients. Periodic monitoring of renal function and serum potassium levels is recommended for all susceptible patients due to documented risks of impairment and hyperkalemia.

Overdose and Emergency Response

Overdose and when to seek help

The following information is based strictly on the official prescribing details for Losartan potassium (Lortaan) provided by regulatory authorities such as the FDA and the EMA.

Documented Overdose Manifestations

Classification Symptom or Condition
Most Likely Symptom Hypotension (severely low blood pressure)
Heart Rate Changes Tachycardia (fast heartbeat) or Bradycardia (slow heartbeat)
Severe Outcome Profound Hypotension (severe low blood pressure)

The symptoms observed following an overdose are dependent on the extent of the overdose and primarily affect the circulatory system.


Required Emergency Actions

If an overdose is suspected, you must seek immediate medical attention and contact your doctor immediately. The goal of professional treatment is the stabilisation of the circulatory system, which is the priority in managing this condition.

Management Protocol Action Documented in Labeling
Immediate Action Seek immediate medical attention
Initial Measure Administration of activated charcoal (after oral intake)
Treatment Focus Treatment is symptomatic and supportive
Monitoring Close monitoring of vital parameters is required

Lortaan's active ingredient, Losartan, is not removed by haemodialysis, as documented in the official regulatory information.

Therapeutic Uses of Lortaan

Main uses of Lortaan

Lortaan contains losartan, an active substance belonging to a class of medications known as angiotensin II receptor antagonists. It is primarily used to manage specific cardiovascular and renal conditions by influencing the hormonal system that regulates blood pressure and fluid balance.

Treatment of Essential Hypertension

The primary application of Lortaan is the treatment of essential hypertension in adults, as well as in children and adolescents aged 6 to 18 years. High blood pressure increases the workload on the heart and arteries. If left unmanaged, it can lead to long-term damage to the blood vessels of the brain, heart, and kidneys, potentially resulting in stroke, heart failure, or kidney failure. By blocking the action of angiotensin II—a substance that causes blood vessels to tighten—losartan helps the blood vessels relax, leading to a reduction in blood pressure.

Renal Protection in Type 2 Diabetes

Lortaan is indicated for the treatment of kidney disease in adult patients who have both hypertension and type 2 diabetes. In these individuals, the medication is used to help protect renal function. It is often used as part of a comprehensive antihypertensive regimen for patients who show clinical evidence of protein in the urine (proteinuria) and elevated serum creatinine levels, helping to delay the progression of kidney damage.

Reduction of Stroke Risk

In adult patients with hypertension and a specific heart condition known as left ventricular hypertrophy (thickening of the walls of the left ventricle), Lortaan is used to reduce the risk of stroke. This benefit is related to its ability to lower blood pressure and manage the cardiovascular strain associated with an enlarged heart.

Management of Chronic Heart Failure

Lortaan may be used in the treatment of chronic heart failure when therapy with specific other medications, such as Angiotensin-Converting Enzyme (ACE) inhibitors, is considered unsuitable. It is typically utilized in patients whose heart function is reduced, helping to improve clinical outcomes in stable cases.

Benefits of Treatment

  • Blood Pressure Control: Effective lowering of systemic blood pressure to reduce the risk of cardiovascular events.
  • Organ Protection: Helps safeguard the kidneys from damage related to diabetes and reduces the strain on the heart muscle.
  • Vascular Relaxation: Promotes the widening of blood vessels, which facilitates easier blood flow throughout the body.

Regulatory References

  1. NIH DailyMed Professional Labeling

Eligibility and Restrictions for Use

Lortaan (losartan) is a prescription medication used to treat high blood pressure (hypertension), reduce the risk of stroke in patients with high blood pressure and an enlarged heart, and manage kidney problems (nephropathy) in patients with type 2 diabetes and hypertension. It is generally suitable for use in adults and children six years of age and older for hypertension.


Contraindications

Lortaan is not suitable for all patients. It must not be used in the following circumstances due to the risk of serious harm:

Condition Reason for Contraindication
Pregnancy Can cause fetal injury and death, especially in the second and third trimesters. It must be discontinued as soon as pregnancy is detected.
Allergy Known hypersensitivity to losartan or any component of the tablet, or a history of angioedema (severe swelling) related to previous use of an Angiotensin II Receptor Blocker (ARB).
Diabetes and Aliskiren Use with the medication aliskiren is contraindicated in patients who have diabetes, due to an increased risk of kidney problems, low blood pressure, and high blood potassium.

Cautions and Special Populations

Use of Lortaan requires special caution and monitoring in patients with severe kidney impairment (renal insufficiency) or liver impairment (hepatic dysfunction). It is also generally not recommended for women who are breastfeeding. Pediatric patients under six years old have limited data on safety and efficacy.

What should I know about interactions with other medicines?

Lortaan’s official regulatory profile identifies several substance interactions that affect its action or the risk profile for co-administered medicines. The highest-level restriction is the contraindication of co-administering Lortaan with Aliskiren in patients who have diabetes mellitus. The combination with Sparsentan is also prohibited due to documented risks of increased hypotension, hyperkalemia, and changes in renal function.


Pharmacodynamic and Clearance Interactions

Co-administration with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium is officially associated with a risk of hyperkalemia (elevated serum potassium). Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, may reduce the antihypertensive effect of Lortaan and increase the risk of renal impairment. Lortaan is also documented to reduce the renal clearance of Lithium, leading to an increased risk of Lithium toxicity.


Metabolic and Exposure Effects

Lortaan is metabolized by CYP2C9 and CYP3A4 enzymes, leading to pharmacokinetic interactions with medicines that affect these pathways. For example, strong inhibitors of CYP2C9, such as Fluconazole, are documented to significantly increase Losartan exposure while decreasing the exposure of its active metabolite. Food ingestion slows the rate of Losartan absorption and decreases the peak plasma concentration, although the effect on total systemic exposure is minor. Patients with hepatic impairment may exhibit higher concentrations of Losartan.

Mechanism of Action

Lortaan is a human monoclonal antibody designed to interfere with bone remodeling processes by targeting a specific signaling axis. The molecule binds with high affinity to Receptor Activator of Nuclear factor Kappa B Ligand (RANKL), a critical cytokine within the skeletal microenvironment.

This binding action neutralizes soluble and membrane-bound RANKL, preventing its interaction with the RANK receptor expressed on the surface of pre-osteoclasts and mature osteoclasts. By blocking the RANKL/RANK signaling cascade, Lortaan inhibits the differentiation, activation, and survival of osteoclasts. The consequence of this cellular modulation is a rapid and sustained reduction in bone resorption rate. This mechanism directly influences the bone remodeling equilibrium, promoting a shift toward net bone formation activity without introducing any therapeutic claims or patient-relevant outcomes.

Dosage and Administration Information

How to Use Lortaan

This section outlines the standardized administration and dosing principles for Lortaan (Losartan potassium), focusing strictly on procedural use.

Lortaan is exclusively for oral administration, utilizing a film-coated tablet that must be swallowed whole with a glass of water. The medicine may be taken with or without food, establishing a flexible daily timing. For most uses, the frequency is once daily.

Dosing and Regimen

The standard initial dose for conditions such as hypertension is 50 mg once daily. This can be maintained or adjusted within a daily range of 50 mg to 100 mg. For patients who have fluid volume depletion (such as those on high-dose diuretics) or those with hepatic impairment, a lower starting dose of 25 mg once daily is necessary to initiate treatment appropriately.

For chronic conditions, Losartan is used as part of a long-term management plan. Dose titration may be required: for heart failure management, for instance, the initial dose of 12.5 mg is typically doubled at weekly intervals under professional supervision. The full antihypertensive effect is generally achieved 3 to 6 weeks after the start of therapy. If a scheduled dose is missed, patients should resume the regimen by taking the next dose at the regular time, without doubling the dose.

Population-specific rules apply to different patient groups. For children aged 6 to 16, a weight-based dose starting at 0.7 mg/kg once daily is specified, not to exceed 50 mg initially. For older adults, a reduced starting dose of 25 mg may be considered.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lortaan


Evidence for Use in Chronic High Blood Pressure

Research examining Losartan (Lortaan) for high blood pressure is based on large-scale Randomized Controlled Trials (RCTs). These studies explored how Losartan compares to a placebo (an inactive substance) and to other types of blood pressure medications. The trials were used in research exploring how blood pressure measurements change over short periods, as well as tracking major cardiovascular outcomes like heart attack and stroke over extended periods of sim 5 years.

In these studies, Losartan was evaluated in general adult populations with essential hypertension. The findings describe patterns observed in the studies, where research examined changes in blood pressure readings. The collection of evidence for this application includes many large trials.


Evidence for Use in Managing Stroke Risk in Specific Hypertensive Patients

Losartan was evaluated in a major, long-term randomized outcome trial specifically for older adults (aged ge 55) with high blood pressure who also had evidence of an enlarged heart muscle, known as Left Ventricular Hypertrophy (LVH). This research explored if using Losartan was associated with a different pattern of major cardiovascular events.

Findings indicate that the reported incidence of these cardiovascular events differed between the Losartan group and the comparator group used in the trial. The study monitored for the occurrence of events such as fatal or nonfatal stroke. Subgroup findings are uncertain for specific populations; for instance, the evidence for the stroke outcome for Black patients in this trial was limited, as this subgroup's pattern was not the same as the overall cohort observed in the research.


Evidence for Kidney Protection in Diabetic Nephropathy

Clinical research exploring Losartan's role in kidney health involved large-scale, randomized, placebo-controlled trials. These studies were focused on patients with Type 2 Diabetes who also had high blood pressure and signs of kidney stress, such as proteinuria (excess protein in the urine).

Researchers monitored for outcomes capturing phases of heightened symptom activity, such as the onset of End-Stage Renal Disease (ESRD). Findings describe patterns observed, with the Losartan group having a reported rate of reaching the severe composite renal endpoint that differed from the placebo group. Research provides insufficient data regarding primary prevention—meaning studies focused on patients who do not yet have signs of kidney stress.

Key Studies & References

  1. Losartan: DailyMed (Official FDA Labeling)
  2. Losartan - StatPearls (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Lortaan (FAQ)

Q: How quickly does Lortaan start working for its intended use?

A: Losartan has been documented to begin reducing blood pressure after the first dose. However, the full blood pressure-lowering effect is typically achieved after taking the medication consistently for three to six weeks, as it is used as a long-term therapy.

Q: Is it normal to feel a bit dizzy when first starting Lortaan?

A: Dizziness is listed in official documents as a common side effect of Lortaan. Low blood pressure, which can cause dizziness, is noted as being more likely to occur when therapy is first initiated in susceptible patients.

Q: Does Lortaan have a high risk of interaction with over-the-counter pain relievers?

A: Official regulatory documents indicate that Lortaan can interact with a type of pain reliever called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes many over-the-counter options. Co-administration with NSAIDs is documented to potentially decrease the blood pressure-lowering effect and increase the likelihood of renal impairment.

Q: Can Lortaan affect kidney function over time?

A: Lortaan is indicated for kidney protection in certain diabetic patients. However, changes in renal function, including acute renal failure, have been reported in other susceptible individuals. Official safety information indicates that periodic monitoring of kidney function is advised for all susceptible patients.

Q: What are the general guidelines for using Lortaan in older patients?

A: General guidelines from regulatory sources suggest that no initial dosage adjustment is typically necessary for older adults. However, a reduced starting dose may be considered by a healthcare provider for older patients who are volume-depleted or have existing liver impairment.

Q: Can Lortaan cause changes in potassium levels?

A: Losartan, the active ingredient, is associated with a possibility of hyperkalemia, which means elevated serum potassium. Due to this possibility, periodic monitoring of serum potassium levels is advised for susceptible patients.

Q: Is it common for Lortaan to be combined with other medicines in one pill?

A: Yes, while Lortaan itself is a single-ingredient product, the active substance Losartan is commercially available in combination products. These combined tablets are often prescribed with a diuretic (or 'water pill') to treat high blood pressure.

Q: What is the expected time for any potential side effects to show up after starting Lortaan?

A: There is no single expected time for all possible side effects. Official documents note that symptomatic low blood pressure (hypotension) is more likely to occur upon the very first initiation of treatment in patients who are volume- or salt-depleted.

Q: Does taking Lortaan affect the ability to drive or operate machinery?

A: Official product information notes that side effects such as dizziness or somnolence (sleepiness) may occur. These effects could potentially impair a person's ability to drive or operate machinery, particularly when starting therapy or after a dose change.

Q: Can Lortaan be taken with a multivitamin?

A: While general multivitamins are not typically listed as interacting, official guidance advises against taking potassium supplements or potassium-containing salt substitutes without a healthcare provider's direction. This is due to the documented potential for these products to contribute to elevated potassium levels when taken with Lortaan.

Q: Are there any common foods or drinks that should be avoided while taking Lortaan?

A: Regulatory sources advise patients to avoid potassium-containing salt substitutes and potassium supplements, as these can elevate potassium levels. Official information states that alcohol use can enhance the blood pressure-lowering effect and related dizziness. Grapefruit juice has also been documented to potentially decrease Lortaan's efficacy in some patients.

Q: Is Lortaan considered a drug that needs to be taken forever?

A: Lortaan is indicated for the long-term management of chronic conditions such as high blood pressure. The goal is to provide sustained risk reduction for cardiovascular events. The duration of therapy is a decision made by a healthcare professional based on the specific condition being treated.

Q: What if I experience a very rare side effect mentioned in official documents?

A: Official documents list certain serious, rare side effects, such as angioedema (severe swelling of the face, lips, or throat). If signs of a serious reaction, such as angioedema, occur, seeking emergency medical attention is necessary.

Q: Can Lortaan be used by younger adults?

A: Yes, Losartan is indicated for the treatment of high blood pressure in adults. It is also approved for use in pediatric patients who are 6 years of age and older.

Q: Does Lortaan have any known interactions with herbal supplements?

A: Official guidance advises patients to inform their healthcare providers about all prescription, non-prescription medications, vitamins, and herbal products being taken. This is essential for managing potential interactions.

Q: How does Lortaan compare to older classes of blood pressure medication?

A: Lortaan is an Angiotensin II Receptor Blocker (ARB). Official information indicates that this class of drugs is associated with a lower incidence of cough compared to another related class of blood pressure medicine called ACE inhibitors.

Q: What happens if Lortaan is stopped suddenly?

A: Abruptly stopping an antihypertensive medication, such as Lortaan, can lead to a rapid or uncontrolled increase in blood pressure. Decisions about discontinuing therapy should be made in consultation with a healthcare provider.

Q: Is Lortaan safe to take before surgery?

A: Continuing Lortaan before surgery may increase the risk of developing low blood pressure (hypotension) during the procedure. The decision on whether to continue the medication before surgery is made on an individualized basis by the surgical and anesthesia team.

Q: Is there a generic version of Lortaan?

A: Yes, Lortaan is a brand name. The active substance, Losartan potassium, is the generic name and is widely available from various manufacturers as Losartan Potassium Tablets USP.

Q: Can Lortaan cause coughing as a side effect?

A: Cough is listed as a potential side effect in official regulatory documents. However, this side effect is often reported to be less common with ARBs like Losartan compared to ACE inhibitors, which are a related class of blood pressure medication.

Q: Is Lortaan addictive?

A: Losartan is not classified as a controlled substance by major regulatory bodies. Official data indicates that the drug is not considered to have high addictive potential or be a drug of abuse.

Q: How does Lortaan affect blood sugar levels?

A: Lortaan is approved for treating kidney issues in patients with Type 2 Diabetes. Clinical studies suggest the drug is considered 'metabolically neutral,' meaning it does not significantly affect insulin sensitivity or blood sugar levels.

Q: Is it possible to take Lortaan for a short time only?

A: Lortaan is primarily indicated for the long-term management of chronic conditions like high blood pressure to provide sustained risk reduction. The duration of therapy is a clinical decision determined by a healthcare professional based on the specific condition being treated.

Q: What are the potential interactions with cold and flu medications?

A: Many cold and flu medications contain ingredients like NSAIDs or sympathomimetics. These components are documented to either reduce Lortaan's effectiveness in lowering blood pressure or potentially cause adverse cardiovascular effects in susceptible patients.

How should Lortaan be stored and disposed of?

Lortaan (losartan) tablets must be stored at room temperature, away from excess heat, light, and moisture (for example, not in a bathroom cabinet). Keep the medication in the container it was provided in, tightly closed.

Safe Storage

Store Lortaan securely, out of sight and reach of children and others. Many containers are not fully child-resistant, so always lock safety caps and place the medication in a location that is not easily accessible.

Proper Disposal

The best way to dispose of unused or expired Lortaan is to immediately use an available drug take-back option (drop-off site or mail-back envelope). If a take-back program is not available, Lortaan may be disposed of in the household trash. To do this, mix the tablets with an undesirable substance, such as used coffee grounds or kitty litter, and place the mixture in a sealed container or bag before discarding it in the trash. Do not flush Lortaan down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lortaan found in:

A-Z Index: